scorecardresearch
Add as a preferred source on Google
Wednesday, November 12, 2025
TopicVaccine

Topic: Vaccine

Not Oxford lab, not US company, Covid solution will come from India, China pharma industry

Fast and mass pharma production in India and China is crucial if the coronavirus pandemic is to be brought under control.

Are people who have had Covid-19 immune? Perhaps not

What needs to happen now is a series of studies to determine whether the presence of antibodies is associated with protection against re-infection with SARS-CoV-2.

Covid vaccine makers may need to infect subjects to get results

As the infection rate changes, companies running drug trials will face a new problem — not enough test subjects in their regions.

Indian vaccine ventures with global partners could move to human trials soon: VijayRaghavan

At least 14 vaccine candidates being developed solely by Indian players, but none ready for human trials stage yet, Principal Scientific Adviser K. VijayRaghavan says.

Why vaccines should not be immune to market forces

Market prices for vaccines could ensure additional production, help differentiate between vaccines, and even allocation of resources.

Green shoots emerge in world economy as virus lockdowns ease

Indicators such as electricity demand and traffic congestions point to a modest 'lift of lows', as economic recovery remains uneven in the absence of a vaccine.

There will be more than one coronavirus vaccine, and that will be a merry situation

With over 70 vaccine candidates, the end of the Covid crisis will likely be multiple vaccines, some more traditional and others based on emerging technologies.

US pharma giant Merck hopes to beat coronavirus with a pill and two vaccines

Merck bought rights to develop a promising antiviral and will work with partners to advance candidate vaccines based on the technology behind Ebola and measles immunizations.

Xi Jinping is seeking to beat Trump in the race for a coronavirus vaccine

China has promised to share any successful vaccine globally, and would wield immense geopolitical clout if it produces one of the world’s first working shots.

Chinese vaccine shows promise in early human trial, generates immune response against Covid

The vaccine developed by CanSino Biologics is the first candidate to be tested in human trials.

On Camera

BBC scandal: Britain’s elite establishment is rapidly sinking

The impact of all this upheaval is unmooring. We search for the BBC to confirm that Britain still exists and find it missing.

India’s factory data may get reality check in MoSPI’s new IIP plan, defunct factories to be dropped

MoSPI proposes to remove closed factories from IIP sample, aiming for truer picture of India’s industrial health in upcoming 2022–23 base series. Plan open to public feedback until 25 November.

‘Let them see’: Putin says new nuclear-powered missiles in the making, in message to Washington

At a ceremony felicitating Russian military engineers, Putin highlights Moscow’s 'parity' in defence technologies for the next century.

Bihar is where politics moves, and everything else stands still

Bihar is blessed with a land more fertile for revolutions than any in India. Why has it fallen so far behind then? Constant obsession with politics is at the root of its destruction.